Landscape of somatic alterations in large-scale solid tumors from an Asian population

作者：Liqun Wu, Herui Yao, Hui Chen, Aodi Wang, Kun Guo, Wenli Gou, Yanfei Yu, Xiang Li, Ming Yao, S. H. Yuan, Fei Pang, Jinwei Hu, Lijuan Chen, Wenjin Liu, Jicheng Yao, Shuirong Zhang, Xiaowei Dong, Weifeng Wang, Jing Hu, Qi Ling, Songming Ding, Yan Wei, Qiang Li, Weichun Cao, Shuang Wang, Di Yang, Feiling Feng, Gang Zhao, Jian Zhang, Ling Huang, Jia Xu, Wangjun Yan, Zhongsheng Tong, Da Jiang, Tao Ji, Qiao Li, Ling Xu, Huiying He, Liang Shang, Jin Liu, Kefeng Wang, Kefeng Wang, Duoguang Wu, Jingnan Shen, Ye Liu, Ting Zhang, Chaojie Liang, Yanhong Shang, Yanhong Shang, Jianji Guo, Guanbiao Liang, Shifeng Xu, Junfeng Liu, Minghui Wang, Kai Wang, Minghui Wang · 发表于：Nature Communications · 年份：2022 · DOI：10.1038/s41467-022-31780-9 · 被引用次数：128 · 研究领域：Cancer Genomics and Diagnostics、Ferroptosis and cancer prognosis、Cancer Immunotherapy and Biomarkers

Extending the benefits of tumor molecular profiling for all cancer patients requires a comprehensive analysis of tumor genomes across distinct patient populations worldwide. In this study, we perform deep next-generation DNA sequencing (NGS) from tumor tissues and matched blood specimens from over 10,000 patients in China by using a 450-gene comprehensive assay, developed and implemented under international clinical regulations. We perform a comprehensive comparison of somatically altered genes, the distribution of tumor mutational burden (TMB), gene fusion patterns, and the spectrum of various somatic alterations between Chinese and American patient populations. Here, we show 64% of cancers from Chinese patients in this study have clinically actionable genomic alterations, which may affect clinical decisions related to targeted therapy or immunotherapy. These findings describe the similarities and differences between tumors from Chinese and American patients, providing valuable information for personalized medicine.